GENETICS MECHANISMS AND CLINICAL PHENOTYPES OF ARRHYTHMOGENIC CARDIOMYOPATHY

Recruiting

1 years - 99 years

All

Phase 4

1 Location

Brief description of study

The well-established, consistent and precise phenotyping developed in the previous ARVC Registry (and published as the Modified Task Force Criteria), with a comprehensive primary genotyping approach, search for genetic modifiers, and biomarker analysis will fulfill the long-term goals of this proposal to identify the genetic basis of all forms of AVCs (ARVC, ALVC, and aDCM), establish detailed mechanistic and diagnostic understanding, and correlate these findings with clinical phenotypes to improve risk-stratification and better predict adverse events We will test the general hypothesis that mutations in genes encoding final common pathway proteins of the desmosome/cell-cell junction pathway (or its binding partners), lead to disruption of the intercalated disk (IC) and inflammation, causing the clinic-pathologic features of ARVC, ALVC, and aDCM.18,52-55.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Cardiomyopathy
Age: 1 years - 99 years
Gender: All

Updated on 19 Feb 2024. Study ID: 820765

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).